% | $
Quotes you view appear here for quick access.

Forest Laboratories Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • JIMMY123ABC JIMMY123ABC Jul 17, 1998 11:59 AM Flag

    one more thing about wla vs. frx

    I found this info about the pipeline drugs at
    and click on press info and then click on the april
    21,1998 press release.

    -> pregabalin, an
    anticonvulsant, in development for epilepsy, neuropathic pain and
    other CNS disorders. This compound is minimally
    metabolized, making drug interactions unlikely. By the end of
    the year, the company will have initiated more
    25 clinical efficacy studies of this compound. They
    include trials in epilepsy, diabetic neuropathy,
    post-hepatic neuropathy, social phobia, anxiety disorder and

    ->igmesine, a novel antidepressant
    that has demonstrated efficacy in Phase II trials for
    the treatment of major depressive disorder. Its
    unique mode of action offers the
    potential for a more
    rapid onset of action than current therapies with a
    favorable side effect profile.

    ->zenarestat, an
    aldose reductase inhibitor for the treatment and
    prevention of diabetic neuropathy. Licensed from Fujisawa,
    the therapy was shown in Phase II trials to limit and
    even reverse the nerve damage caused by diabetes.

    ->Metaret (suramin), a treatment for hormone refractory
    prostate cancer. In clinical trials, Metaret appears to be
    an effective treatment for the condition, decreasing
    pain scores and pain medication needs, and producing
    clinically significant reductions of the tumor marker PSA
    (Prostatic Specific Antigen). An NDA was filed at the end of

    ->CelexaTM (citalopram), a selective
    serotonin reuptake inhibitor, for the treatment of
    depression. A new drug application for CelexaTM was submitted
    by Forest
    Laboratories, Inc. to the U.S. Food and
    Drug Administration in May 1997. Warner-Lambert
    entered into an agreement with Forest Laboratories in
    March to co-promote the drug.

    (CI-1011), an ACAT inhibitor, which prevents the
    accumulation of atherosclerotic plaque and reduces total
    cholesterol levels. In pre-clinical models, CI-1011
    demonstrated a regression of arterial lesions. In addition,
    effective ACAT inhibitors may reduce total cholesterol
    levels by decreasing absorption of dietary cholesterol
    and reducing hepatic VLDL secretion. Phase III trials
    are expected to
    begin within a year.

    ->CI-1004, an anti-inflammatory that works by dual
    inhibition. It inhibits 5-lipoxygenase, the enzyme
    responsible for leukotrines, and it inhibits the
    cyclooxygenase, COX-2. This dual mechanism of action may provide
    advantages over
    COX-2 inhibition alone as a result of
    enhanced anti-inflammatory efficacy. CI-1004 could
    potentially have the GI safety of the new COX-2 agents with
    improved efficacy over current NSAIDS. Phase II trials for
    rheumatoid arthritis and osteoarthritis are
    expected to
    begin this year.

    ->CI-1001, (ethinyl
    estradiol/norethindrone acetate) an intravaginal ring, provides
    contraception for up to three months. A phase II trial showed
    good cycle control with
    excellent patient tolerance
    and acceptance. Phase III trials in both the U.S. and
    overseas are expected to begin in early 1999.

    ->FemHRT (ethinyl estradiol/norethindrone acetate) is a
    combination estrogen progestin hormone replacement therapy
    for use in treating osteoporosis and perimenopausal
    symptoms. The NDA is expected to be submitted in the U.S.
    within the next 12 months.

    ->clinafloxacin, a
    new generation quinolone anti-infective. This
    compound is effective against highly virulent bacteria,
    including those that are resistant to the most potent

    drugs now available. The compound, for which oral and
    injectible forms are planned, will be for hospital use. An
    NDA is expected to be submitted later this year.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Those so called 10 products in WLA pipeline are
      either in advanced clinical development or are awaiting
      approval. Its not the entire pipeline. WLA entire pipeline
      i'm guessing is around 40-50 products. And FRX
      doesn't have only 1 drug in the pipeline. They have
      Celexa, awaiting approval for an Alzheimer's drug, and
      they've recently in-licensed 3 more compounds from HD
      Lundbeck. Other than those, I'm sure they've got more to
      show for their R&D spending as opposed to the 1 drug
      you believe them to have. Look a little closer next
      time JIMMY, maybe you'll get the right information.